Data indicates that although LSCs are relatively rare, they maintain the disease and are responsible for relapse following chemotherapeutic elimination of the leukemic cell bulk.
In combination with modern chemical or radiation-based therapies, tumor elimination without relapse is an exciting possibility.
In non-IgE-mediated CMA, the value of tests is far more limited, and the clinician needs to rely on history, physical examination, and the results of the elimination diet and relapse upon milk challenge.
This raises the unanswered question of whether elimination of clinical relapses will prevent subsequent progression and if so how early in the disease course should treatment be initiated.
We show that elimination of clinical relapses by immunological tolerance, even after the first clinical event, although partially neuroprotective is, of itself, insufficient to prevent ongoing and significant neurodegeneration (1,26,36).
Relapses contribute to increased morbidity, and complicate malaria elimination programs.
Nevertheless, we propose that the benefit of patients treated with a taxane-based regimen in terms of DFS and disease relapse rate should be due to a more effective elimination of CK-19 CTCs due to the administration of taxanes.
Therefore, alternative therapeutic options that improve elimination of DTC may reduce the risk of relapse and improve survival in early breast cancer patients.
For these reasons, alternative therapeutic options that improve elimination of DTCs may reduce the risk of relapse and improve survival in patients with EBC.
When comparing all triptan trials, the elimination half-life time is inversely correlated with the relapse rate (r = −1.0; p = 0.0016).
